HHS grants enforcement discretion for six popular wellness peptides

The Department of Health and Human Services issued a new policy on Tuesday that grants enforcement discretion for six specific peptides. The move allows small compounding pharmacies to manufacture these compounds without facing federal penalties. Health Secretary Robert F. Kennedy Jr., who has publicly used the substances, championed the decision. The peptides are short chains of amino acids that wellness influencers promote for various conditions, despite a lack of rigorous clinical evidence.

The six compounds targeted by the new rule are BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. Proponents cite potential benefits for ulcerative colitis, insomnia, wound healing, metabolic health, and migraines. Until now, these peptides occupied a legal gray zone. They were widely available online from overseas suppliers labeled as research-use-only, but technically banned from being compounded by pharmacies.

The path to this policy began in July, when an FDA advisory panel voted to support expanded access. However, the agency’s own scientists recommended against lifting the current restrictions during that same meeting. The HHS policy now prioritizes compounding as a safer alternative to the illicit online market. The administration argues that bringing production into regulated pharmacies ensures better quality control than sourcing from sketchy foreign vendors.

The rule applies only to 503A compounding pharmacies, which operate as smaller, local facilities. It does not extend to 503B outsourcing facilities that produce larger volumes of medicine. This distinction limits the total supply. Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals in central Florida, noted that his company previously avoided making these peptides because they were illegal to compound. Under the new guidelines, only his smaller facility can produce them, and likely in limited quantities.

Fritzler expects a shortage. He stated that his company will probably only compound one of the six peptides and must first prepare its facility. He predicts that the nationwide network of 503A pharmacies will struggle to meet consumer demand. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, supported the move in a written statement. He described the change as a more accountable alternative that subjects the products to standard pharmacy oversight and adverse event reporting.

Critics argue the policy bypasses standard safety checks. Public Citizen, a nonprofit advocacy group, contended that Kennedy acted unilaterally instead of using the typical rulemaking process. Dr. Robert Steinbrook, a health research director at the group, wrote that the decision undermines the FDA. He advised clinicians to warn patients about the risks of contamination and other adverse effects from unproven substances. Steinbrook called for all peptides to undergo the standard new drug approval process.

The Partnership for Safe Medicines filed a citizen petition with the FDA last week. The group urged the agency to disregard the July advisory committee recommendation. Shabbir Safda, the partnership’s executive director, said the decision leaves Americans in a gray area regarding safety. He pointed out that FDA scientists had recommended against the change due to insufficient evidence.

Suppliers must now verify that their active ingredients meet the new policy requirements. Pharmacies must also validate these ingredients before dispensing products. Brunner warned that this verification process means it may take time before compounding pharmacies can begin shipping the peptides to patients. The HHS policy does not alter the legal status of the peptides but creates a specific pathway for small-scale production.